ASSEMBLY COMMITTEE SUBSTITUTE FOR **ASSEMBLY, No. 5457**

STATE OF NEW JERSEY 219th LEGISLATURE

ADOPTED MAY 17, 2021

Sponsored by: Assemblywoman VALERIE VAINIERI HUTTLE District 37 (Bergen) Assemblyman ANTHONY S. VERRELLI District 15 (Hunterdon and Mercer) Assemblyman DANIEL R. BENSON District 14 (Mercer and Middlesex)

Co-Sponsored by: Assemblyman Mukherji and Assemblywoman McKnight

SYNOPSIS

Revises and expands authorization for any person or entity to obtain, distribute, and administer opioid antidotes.

CURRENT VERSION OF TEXT

Substitute as adopted by the Assembly Health Committee.



2

AN ACT concerning opioid antidotes, amending various parts of the
 statutory law, and supplementing P.L.2013, c.46 (C.24:6J-1 et
 al.).

4 5

BE IT ENACTED by the Senate and General Assembly of the State of New Jersey:

6 7

8

9

1. Section 2 of P.L.2013, c.46 (C.24:6J-2) is amended to read as follows:

10 2. The Legislature finds and declares that encouraging 11 [witnesses and victims of] people who witness or experience a 12 suspected drug [overdoses] overdose to seek medical assistance saves lives and is in the best interests of the citizens of this State 13 14 and, in instances where evidence was obtained as a result of seeking of medical assistance, [these witnesses and victims] those people 15 16 who witness or experience a suspected drug overdose should be 17 protected from arrest, charge, prosecution, conviction, and 18 revocation of parole or probation for possession or use of illegal 19 drugs or drug paraphernalia. Additionally, naloxone is [an] a safe, 20 inexpensive, and easily administered antidote to an opioid overdose. Encouraging the wider prescription and distribution of naloxone or 21 22 similarly acting drugs to those at risk for an opioid overdose, or to 23 members of their families or peers, would reduce the number of 24 opioid overdose deaths and be in the best interests of the citizens of 25 this State. To that end, it is the intent of the Legislature that opioid 26 antidotes be made as easily accessible and as widely available as 27 possible, such that they are readily available at all times to provide 28 treatment to people experiencing a suspected opioid overdose. It is 29 not the intent of the Legislature to protect individuals from arrest, 30 prosecution or conviction for other criminal offenses, including 31 engaging in drug trafficking, nor is it the intent of the Legislature to 32 in any way modify or restrict the current duty and authority of law 33 enforcement and emergency responders at the scene of a medical 34 emergency or a crime scene, including the authority to investigate 35 and secure the scene.

- 36 (cf: P.L.2013, c.46, s.2)
- 37

38 2. Section 3 of P.L.2013, c.46 (C.24:6J-3) is amended to read 39 as follows:

40 3. As used in this act:

41 "Commissioner" means the Commissioner of Human Services.

42 "Drug overdose" means an acute condition including, but not
43 limited to, physical illness, coma, mania, hysteria, <u>diminished</u>

44 <u>consciousness, respiratory depression</u>, or death resulting from the

45 consumption or use of a controlled dangerous substance or another

EXPLANATION – Matter enclosed in **bold-faced brackets** [thus] in the above bill is not enacted and is intended to be omitted in the law.

Matter underlined <u>thus</u> is new matter.

substance with which a controlled dangerous substance was
 combined and that a layperson would reasonably believe to require
 medical assistance.

4 "Emergency medical response entity" means an organization, 5 company, governmental entity, community-based program, or 6 healthcare system that provides pre-hospital emergency medical 7 services and assistance [to opioid or heroin addicts or abusers in the 8 event of an overdose]. "Emergency medical response entity" 9 includes, but is not limited to, a first aid, rescue and ambulance 10 squad or other basic life support (BLS) ambulance provider; a mobile intensive care provider or other advanced life support (ALS) 11 12 ambulance provider; an air medical service provider; or a fire-13 fighting company or organization, which squad, provider, company, 14 or organization is qualified to send paid or volunteer emergency 15 medical responders to the scene of an emergency.

"Emergency medical responder" means a person, other than a
health care practitioner, who is employed on a paid or volunteer
basis in the area of emergency response, including, but not limited
to, an emergency medical technician, a mobile intensive care
paramedic, or a fire fighter, acting in that person's professional
capacity.

22 "Health care practitioner" means [a prescriber, pharmacist, or 23 other] any individual [whose professional practice is regulated] 24 who is licensed or certified to provide health care services pursuant 25 to Title 45 of the Revised Statutes [, and who, in accordance with 26 the practitioner's scope of professional practice, prescribes or 27 dispenses an opioid antidote].

28 <u>"Institution of higher education" means any public or private</u>
29 <u>university, college, technical college or community college located</u>
30 <u>in New Jersey.</u>

31 <u>"Law enforcement agency" means a department, division,</u>
32 <u>bureau, commission, board or other authority of the State or of any</u>
33 political subdivision thereof which employs law enforcement
34 <u>officers.</u>

35 <u>"Law enforcement officer" means a person whose public duties</u>
 36 <u>include the power to act as an officer for the detection,</u>
 37 <u>apprehension, arrest and conviction of offenders against the laws of</u>
 38 <u>this State.</u>

39 "Medical assistance" means professional medical services that 40 are provided to a person experiencing a drug overdose by a health 41 care practitioner, acting within the practitioner's scope of 42 professional practice, including professional medical services that 43 are mobilized through telephone contact with the 911 telephone 44 emergency service.

45 <u>"Occupational school" means a business, trade, technical, or</u>
 46 <u>other school approved by a nationally-recognized accrediting</u>
 47 <u>agency.</u>

¹ "Opioid antidote" means any drug, regardless of dosage amount ² or method of administration, which has been approved by the ³ United States Food and Drug Administration (FDA) for the ⁴ treatment of an opioid overdose. "Opioid antidote includes, but is ⁵ not limited to, naloxone hydrochloride, in any dosage amount, ⁶ which is administered through nasal spray or any other FDA-⁷ approved means or methods.</sup>

8 ["Patient" means a person who is at risk of an opioid overdose or 9 a person who is not at risk of an opioid overdose who, in the 10 person's individual capacity, obtains an opioid antidote from a 11 health care practitioner, professional, or professional entity for the 12 purpose of administering that antidote to another person in an 13 emergency, in accordance with subsection c. of section 4 of P.L.2013, c.46 (C.24:6J-4). "Patient" includes a professional who is 14 15 acting in that professional's individual capacity, but does not 16 include a professional who is acting in a professional capacity.

"Prescriber" means a health care practitioner authorized by law
to prescribe medications [who, acting within the practitioner's
scope of professional practice, prescribes an opioid antidote].
"Prescriber" includes, but [is] shall not be limited to, [a physician,
physician assistant, or advanced practice nurse] physicians,
physician assistants, and advanced practice nurses.

23 ["Professional" means a person, other than a health care 24 practitioner, who is employed on a paid basis or is engaged on a 25 volunteer basis in the areas of substance abuse treatment or therapy, 26 criminal justice, or a related area, and who, acting in that person's 27 professional or volunteer capacity, obtains an opioid antidote from a 28 health care practitioner for the purposes of dispensing or 29 administering that antidote to other parties in the course of business 30 or volunteer activities. "Professional" includes, but is not limited 31 to, a sterile syringe access program employee, or a law enforcement 32 official.

33 "Professional entity" means an organization, company, 34 governmental entity, community-based program, sterile syringe 35 access program, or any other organized group that employs two or more professionals who engage, during the regular course of 36 37 business or volunteer activities, in direct interactions with opioid or 38 heroin addicts or abusers or other persons susceptible to opioid 39 overdose, or with other persons who are in a position to provide 40 direct medical assistance to opioid or heroin addicts or abusers in 41 the event of an overdose]

42 <u>"Public library" means a library that serves, free of charge, all</u>
43 residents of an area without discrimination and that receives its
44 <u>financial support, in whole or in part, from public funds.</u>

45 <u>"Public transportation hub" means a passenger station, terminal,</u>
 46 <u>or other facility, as designated by the Commissioner of</u>

5

1 Transportation, where public transportation services are made 2 available. 3 "Recipient" means **[**a patient, professional, professional entity, 4 emergency medical responder, emergency medical response entity, 5 school, school district, or school nurse] any individual who or entity that is prescribed or dispensed an opioid antidote in 6 7 accordance with section 4 of P.L.2013, c.46 (C.24:6J-4) or section 1 8 of P.L.2017, c.88 (C.45:14-67.2). The term "recipient" shall 9 include, but shall not be limited to, private citizens, emergency 10 medical responders, emergency medical response entities, law 11 enforcement officers, law enforcement agencies, recognized places 12 of public access, employees and volunteers providing services at, 13 through, or on behalf of a recognized place of public access, public 14 and nonpublic schools, school nurses and other staff at a public or 15 nonpublic school, sterile syringe access programs, and staff and employees of a sterile syringe access program. The term 16 17 "recipient" shall not include a prescriber or a licensed pharmacist 18 acting within a professional capacity. 19 "Recognized place of public access" means a public library, 20 institution of higher education, occupational school, or public 21 transportation hub. 22 "Sterile syringe access program" means a program established pursuant to the provisions of P.L.2006, c.99 (C.26:5C-25 et al.). 23 24 (cf: P.L.2018, c.106, s.7) 25 26 3. Section 4 of P.L.2013, c.46 (C.24:6J-4) is amended to read 27 as follows: 28 4. a. (1) A prescriber or other health care practitioner, as 29 appropriate, may prescribe or dispense an opioid antidote **[**: 30 (a) directly or through a standing order [,] to any [recipient 31 who is deemed by the health care practitioner to be capable of 32 administering the opioid antidote to an overdose victim in an 33 emergency; 34 (b) through a standing order, to any professional or emergency 35 medical responder who is not acting in a professional or volunteer capacity for a professional entity, or an emergency medical 36 37 response entity, but who is deemed by the health care practitioner to 38 be capable of administering opioid antidotes to overdose victims, as 39 part of the professional's regular course of business or volunteer 40 activities; 41 (c) through a standing order, to any professional who is not 42 acting in a professional or volunteer capacity for a professional 43 entity, but who is deemed by the health care practitioner to be 44 capable of dispensing opioid antidotes to recipients, for 45 administration thereby, as part of the professional's regular course 46 of business or volunteer activities; 47 (d) through a standing order, to any professional entity or any 48 emergency medical response entity, which is deemed by the health

6

care practitioner to employ professionals or emergency medical
 responders, as appropriate, who are capable of administering opioid
 antidotes to overdose victims as part of the entity's regular course of
 business or volunteer activities;

5 (e) through a standing order, to any professional entity which is 6 deemed by the health care practitioner to employ professionals who 7 are capable of dispensing opioid antidotes to recipients, for 8 administration thereby, as part of the entity's regular course of 9 business or volunteer activities;

(f) through a standing order, to a school, school district, or
school nurse pursuant to the provisions of section 2 of P.L.2018,
c.106 (C.18A:40-12.24)] person or entity. Any person or entity
may be dispensed an opioid antidote pursuant to an individual
prescription or a standing order issued by a prescriber, and any
person or entity may be dispensed an opioid antidote by a pharmacy
as provided in section 1 of P.L.2017, c.88 (C.45:14-67.2).

17 (2) **[**(a) For the purposes of this subsection, whenever the law 18 expressly authorizes or requires a certain type of professional or 19 professional entity to obtain a standing order for opioid antidotes 20 pursuant to this section, such professional, or the professionals employed or engaged by such professional entity, as the case may 21 22 be, shall be presumed by the prescribing or dispensing health care 23 practitioner to be capable of administering or dispensing the opioid 24 antidote, consistent with the express statutory requirement.

25 (b) For the purposes of this subsection, whenever the law 26 expressly requires a certain type of emergency medical responder or 27 emergency medical response entity to obtain a standing order for 28 opioid antidotes pursuant to this section, such emergency medical 29 responder, or the emergency medical responders employed or 30 engaged by such emergency medical response entity, as the case 31 may be, shall be presumed by the prescribing or dispensing health 32 care practitioner to be capable of administering the opioid antidote, 33 consistent with the express statutory requirement.

34 (c) For the purposes of this subsection, whenever the law 35 expressly authorizes or requires a school or school district to obtain 36 a standing order for opioid antidotes pursuant to this section, the 37 school nurses employed or engaged by the school or school district 38 shall be presumed by the prescribing or dispensing health care 39 practitioner to be capable of administering the opioid antidote, 40 consistent with the express statutory requirement] Nothing in 41 P.L.2013, c.46 (C.24:6J-1 et al.) shall be construed to restrict in any 42 way the ability of any individual or entity to be dispensed an opioid 43 antidote. The persons and entities to whom an opioid antidote may 44 be prescribed and dispensed shall include private citizens, 45 individuals who are dispensed an opioid antidote for administration 46 or distribution to others in either a private or professional capacity, 47 entities that are dispensed opioid antidotes on behalf of individuals 48 who administer or distribute opioid antidotes to others in the course

7

1 of their professional duties, and entities other than a prescriber or

- 2 pharmacist that maintain a stock of opioid antidotes for distribution
- 3 <u>or administration to others</u>.

4 (3) **[**(a) Whenever a prescriber or other health care practitioner 5 prescribes or dispenses an opioid antidote to a professional or professional entity pursuant to a standing order issued under 6 7 paragraph (1) of this subsection, the standing order shall specify 8 whether the professional or professional entity is authorized thereby 9 to directly administer the opioid antidote to overdose victims; to 10 dispense the opioid antidote to recipients, for their administration to 11 third parties; or to both administer and dispense the opioid antidote. 12 If a standing order does not include a specification in this regard, it 13 shall be deemed to authorize the professional or professional entity 14 only to administer the opioid antidote with immunity, as provided 15 by subsection c. of this section, and it shall not be deemed to 16 authorize the professional or professional entity to engage in the 17 further dispensing of the antidote to recipients, unless such 18 authority has been granted by law, as provided by subparagraph (b) 19 of this paragraph.

20 (b) Notwithstanding the provisions of this paragraph to the 21 contrary, if the law expressly authorizes or requires a certain type of 22 professional, professional entity, emergency medical responder, 23 emergency medical response entity, school, school district, or 24 school nurse to administer or dispense opioid antidotes pursuant to 25 a standing order issued hereunder, the standing order issued 26 pursuant to this section shall be deemed to grant the authority 27 specified by the law, even if such authority is not expressly 28 indicated on the face of the standing order.] (deleted by 29 amendment, P.L., c.) (pending before the Legislature as this 30 bill)

31 (4) [Any prescriber or other health care practitioner who 32 prescribes or dispenses an opioid antidote in good faith, and in 33 accordance with the provisions of this subsection, shall not, as a 34 result of the practitioner's acts or omissions, be subject to any 35 criminal or civil liability, or any professional disciplinary action under Title 45 of the Revised Statutes for prescribing or dispensing 36 37 an opioid antidote in accordance with P.L.2013, c.46 (C.24:6J-1 et seq.).] (deleted by amendment, P.L., c.) (pending before the 38 39 Legislature as this bill)

40 b. (1) [Any professional or professional entity that has 41 obtained a standing order, pursuant to subsection a. of this section, 42 for the dispensing of opioid antidotes, may dispense an opioid 43 antidote to any recipient who is deemed by the professional or 44 professional entity to be capable of administering the opioid 45 antidote to an overdose victim in an emergency A recipient in 46 possession of an opioid antidote may administer the opioid antidote 47 to any other person, without fee, in any situation in which the

8

recipient reasonably believes the other person to be experiencing an
 opioid overdose.

3 (2) [Any professional or professional entity that dispenses an 4 opioid antidote in accordance with paragraph (1) of this subsection, 5 in good faith, and pursuant to a standing order issued under 6 subsection a. of this section, shall not, as a result of any acts or 7 omissions, be subject to any criminal or civil liability or any 8 professional disciplinary action for dispensing an opioid antidote in 9 accordance with P.L.2013, c.46 (C.24:6J-1 et seq.) A recipient in 10 possession of an opioid antidote may distribute the opioid antidote, without fee, to any other person who the recipient reasonably 11 12 believes to be at risk of experiencing an opioid overdose or who the 13 recipient reasonably believes will be in a position to administer the 14 opioid antidote to a person experiencing an opioid overdose. A 15 recipient distributing an opioid antidote to another person pursuant 16 to this paragraph shall make reasonable efforts to furnish the person 17 with the overdose prevention information described in section 5 of 18 P.L.2013, c.46 (C.24:6J-5). The Commissioner of Health, or, if the 19 commissioner is not a duly licensed physician, the Deputy 20 Commissioner for Public Health Services, shall issue a standing 21 order authorizing the distribution of opioid antidotes pursuant to 22 this paragraph.

23 c. (1) [Any emergency medical responder or emergency 24 medical response entity that has obtained a standing order, pursuant 25 to subsection a. of this section, for the administration of opioid antidotes, may administer an opioid antidote to overdose victims **]** <u>A</u> 26 27 prescriber or other health care practitioner who prescribes or 28 dispenses an opioid antidote in good faith, and in accordance with 29 the provisions of this section, shall not, as a result of the 30 practitioner's acts or omissions, be subject to any criminal or civil liability, or any professional disciplinary action under Title 45 of 31 32 the Revised Statutes, for prescribing or dispensing the opioid 33 antidote. A pharmacist that dispenses an opioid antidote in good 34 faith, in accordance with the provisions of this section or section 1 of P.L.2017, c.88 (C.45:14-67.2), shall not, as a result of the 35 36 pharmacist's acts or omissions, be subject to any criminal or civil 37 liability, or any professional disciplinary action under Title 45 of 38 the Revised Statutes, for dispensing the opioid antidote.

39 (2) [Any emergency medical responder or emergency medical 40 response entity that administers an opioid antidote, in good faith, in 41 accordance with paragraph (1) of this subsection, and pursuant to a 42 standing order issued under subsection a. of this section, shall not, 43 as a result of any acts or omissions, be subject to any criminal or 44 civil liability, or any disciplinary action, for administering the 45 opioid antidote in accordance with P.L.2013, c.46 (C.24:6J-1 et seq.) <u>A recipient who administers or distributes an opioid antidote</u> 46 47 in good faith as provided in subsection b. of this section shall not,

9

1 as a result of any of the recipient's acts or omissions, be subject to

- 2 any criminal or civil liability, or any professional disciplinary
- 3 <u>action, for administering or distributing the opioid antidote</u>.

d. **[**(1) Any person who is the recipient of an opioid antidote, which has been prescribed or dispensed for administration purposes pursuant to subsection a. or b. of this section, and who has received overdose prevention information pursuant to section 5 of P.L.2013, c.46 (C.24:6J-5), may administer the opioid antidote to another person in an emergency, without fee, if the antidote recipient believes, in good faith, that the other person is experiencing an

11 opioid overdose.

(2) Any person who administers an opioid antidote pursuant to
paragraph (1) of this subsection shall not, as a result of the person's
acts or omissions, be subject to any criminal or civil liability for
administering the opioid antidote in accordance with P.L.2013, c.46
(C.24:6J-1 et seq.).] (deleted by amendment, P.L. , c.) (pending
before the Legislature as this bill)

18 [In addition to the] The immunity [that is] provided by this e. 19 section for [authorized] persons who are engaged in [the] 20 prescribing, dispensing, distributing, or administering [of] an 21 opioid antidote [,] shall be coextensive with the immunity provided 22 [by section 7 or section] under sections 7 and 8 of P.L.2013, c.46 23 (C.2C:35-30 [or] and C.2C:35-31) [shall apply to a person who 24 acts in accordance with this section, provided that the requirements 25 of], to the extent that the provisions of those sections [, as 26 applicable, have been met **]** <u>apply</u>.

27 f. [Any school, school district, school nurse, school employee, 28 or any other officer or agent of a board of education, charter school, 29 or nonpublic school who administers, or permits the administration 30 of, an opioid antidote in good faith in accordance with the 31 provisions of section 2 of P.L.2018, c.106 (C.18A:40-12.24), and 32 pursuant to a standing order issued under subsection a. of this 33 section, shall not, as a result of any acts or omissions, be subject to 34 any criminal or civil liability, or any disciplinary action, for 35 administering, or for permitting the administration of, the opioid 36 antidote in accordance with P.L.2013, c.46 (C.24:6J-1 et seq.).] (deleted by amendment, P.L., c.) (pending before the 37 38 Legislature as this bill)

g. [Notwithstanding the provisions of any law, rule, regulation,
ordinance, or institutional or organizational directive to the
contrary, any person or entity authorized to administer an opioid
antidote pursuant to this section, may administer to an overdose
victim, with full immunity:

44 (1) a single dose of any type of opioid antidote that has been
45 approved by the United States Food and Drug Administration for
46 use in the treatment of opioid overdoses; and

10

(2) up to three doses of an opioid antidote that is administered 1 2 through an intranasal application, or through an intramuscular auto-3 injector, as may be necessary to revive the overdose victim. Prior 4 consultation with, or approval by, a third-party physician or other 5 medical personnel shall not be required before an authorized person 6 or entity may administer up to three doses of an opioid antidote, as 7 provided in this paragraph, to the same overdose victim.] (deleted 8 by amendment, P.L., c.) (pending before the Legislature as this 9 bill) 10 h. No later than 45 days after the effective date of P.L.2017, c.381 the Commissioner of Health shall provide written notice to all 11 12 emergency medical response entities affected by subsection g. of 13 this section notifying them of the provisions of subsection g. of this 14 section.] (deleted by amendment, P.L., c.) (pending before the 15 Legislature as this bill) 16 (cf: P.L.2018, c.106, s.8) 17 18 4. Section 5 of P.L.2013, c.46 (C.24:6J-5) is amended to read 19 as follows: 20 5. a. (1) A prescriber or other health care practitioner who 21 prescribes or dispenses an opioid antidote in accordance with 22 subsection a. of section 4 of P.L.2013, c.46 (C.24:6J-4), and a 23 pharmacist who dispenses an opioid antidote pursuant to subsection 24 a. of section 4 of P.L.2013, c.46 (C.24:6J-4) or section 1 of 25 P.L.2017, c.88 (C.45:14-67.2), shall ensure that overdose prevention information is provided to the [antidote] recipient. The 26 27 [requisite] overdose prevention information shall include, but [is] need not be limited to: information on opioid overdose prevention 28 29 and recognition; instructions on how to perform rescue breathing 30 and resuscitation; information on opioid antidote dosage and 31 instructions on opioid antidote administration; information 32 describing the importance of calling the 911 emergency telephone 33 service for assistance with an opioid overdose; and instructions for 34 appropriate care of [an] a person believed to be experiencing an opioid overdose [victim] after administration of the opioid 35 36 antidote. 37 (2) [A professional or professional entity that dispenses an 38 opioid antidote pursuant to a standing order, in accordance with 39 subsection b. of section 4 of P.L.2013, c.46 (C.24:6J-4), shall 40 ensure that each patient who is dispensed an opioid antidote also 41 receives a copy of the overdose prevention information that has 42 been provided to the professional or professional entity pursuant to 43 paragraph (1) of this subsection.] (deleted by amendment, P.L., 44 c.) (pending before the Legislature as this bill) 45 b. (1) In order to fulfill the information distribution 46 requirements of subsection a. of this section, overdose prevention 47 information may be provided by the prescribing or dispensing

11

health care practitioner, by the dispensing professional or 1 2 professional entity, or by a community-based organization, or other 3 organization that addresses medical or social issues related to drug 4 addiction, and with which the health care practitioner, professional, 5 professional entity, as appropriate, maintains a written or 6 agreement. Any such written agreement shall incorporate, at a 7 minimum: procedures for the timely dissemination of overdose 8 prevention information; information as to how employees or 9 volunteers providing the information will be trained; and standards 10 for recordkeeping under paragraph (2) of this subsection.] (deleted 11 by amendment, P.L., c.) (pending before the Legislature as this 12 bill)

13 (2) The dissemination of overdose prevention information [in 14 accordance with this section, and the contact information for the 15 persons receiving such information, to the extent known,] shall be 16 documented by the prescribing or dispensing health care 17 practitioner **[**, professional, or professional entity, as appropriate, **]** 18 or dispensing pharmacist in [: (a)] the patient's medical record [, if 19 applicable;] or [(b)] another appropriate record [or log, if the 20 patient's medical record is unavailable or inaccessible, or if the 21 antidote recipient is a professional or professional entity acting in 22 their professional capacity; or (c) any], log or other similar 23 recordkeeping location [, as specified in a written agreement that 24 has been executed pursuant to paragraph (1) of this subsection].

c. 25 In order to facilitate the dissemination of overdose 26 prevention information in accordance with this section, the 27 Commissioner of Human Services, in consultation with the 28 Department of Health and Statewide organizations representing 29 physicians, advanced practice nurses, or physician assistants, and 30 organizations operating community-based programs, sterile syringe 31 access programs, or other programs which address medical or social 32 issues related to [drug addiction] substance use disorders, may 33 develop training materials in video, electronic, or other appropriate 34 formats, and disseminate these materials to health care practitioners 35 **[**; professionals and professional entities that are authorized by 36 standing order to dispense opioid antidotes; and organizations that 37 are authorized to disseminate overdose prevention information 38 under a written agreement executed pursuant to paragraph (1) of The Commissioner of Human 39 subsection b. of this section]. 40 Services may make the materials available to the general public 41 through the Internet website of the Department of Human Services, 42 with such modifications as may be appropriate to adapt the 43 materials for use by persons who are not health care practitioners. 44 The commissioner shall ensure the materials are available in 45 English, Spanish, and any other language that the commissioner 46 determines is the first language of a significant number of people 47 who are likely to be prescribed or dispensed an opioid antidote in

12

1 accordance with subsection a. of section 4 of P.L.2013, c.46 2 (C.24:6J-4) or dispensed an opioid antidote pursuant to section 1 of 3 P.L.2017, c.88 (C.45:14-67.2). 4 (cf: P.L.2015, c.10, s.3) 5 6 5. Section 1 of P.L.2017, c.285 (C.24:6J-5.1) is amended to 7 read as follows: 8 1. a. If an opioid antidote is administered by a health care 9 [professional] <u>practitioner</u> or a first responder to a person <u>believed</u> 10 to be experiencing a drug overdose, an opioid antidote and information concerning substance [abuse] use disorder treatment 11 12 programs and resources and sterile syringe access programs and 13 resources, including information on the availability of opioid 14 antidotes, shall be provided to the person as follows: 15 (1) If the person is admitted to a health care facility or receives 16 treatment in the emergency department of a health care facility, a 17 staff member designated by the health care facility, who may be a social worker, [addiction] professional counselor, licensed or 18 19 certified alcohol or drug counselor, or other appropriate 20 professional, shall offer to furnish the person, or a family member 21 or friend of the person in attendance during the patient's admission 22 or emergency department visit, with an opioid antidote upon 23 discharge, along with information regarding the cost of the opioid 24 antidote, and shall provide the information concerning substance 25 use disorder treatment programs and resources and sterile syringe 26 access programs and resources to the person at any time after 27 treatment for the drug overdose is complete, but prior to the 28 person's discharge from the facility. The designated staff member 29 shall document the provision of the information and the dispensing 30 of an opioid antidote to the person or to a family member or friend 31 of the person, if an opioid antidote is dispensed, in the person's 32 medical record, and may, in collaboration with an appropriate 33 health care [professional] practitioner, additionally develop an 34 individualized substance [abuse] use disorder treatment plan for 35 the person. 36 (2) If the opioid antidote is administered by a first responder and 37 the person <u>believed to be</u> experiencing [the] <u>an</u> overdose is not 38 subsequently transported to a health care facility, the first responder 39 shall offer to furnish the person with an opioid antidote and shall 40 provide the information concerning substance use disorder 41 treatment programs and resources and sterile syringe access 42 programs and resources to the person at the time treatment for the 43 drug overdose is complete. First responders shall maintain an 44 adequate supply of opioid antidotes, in excess of the supply needed 45 to meet the anticipated demand for opioid antidotes to treat 46 individuals believed to be experiencing an opioid overdose, as is 47 necessary to ensure people treated for a suspected opioid overdose

13

can be furnished with an opioid antidote at the time treatment for 1 2 the overdose is complete. 3 b. As used in this section: 4 "First responder" means a law enforcement officer, paid or 5 volunteer firefighter, paid or volunteer member of a duly 6 incorporated first aid, emergency, ambulance, or rescue squad 7 association, or any other individual who, in the course of that 8 individual's employment, is dispatched to the scene of an 9 emergency situation for the purpose of providing medical care or 10 other assistance. 11 "Health care facility" means a health care facility licensed 12 pursuant to P.L.1971, c.136 (C.26:2H-1 et seq.). "Opioid antidote" means any drug, regardless of dosage amount 13 14 or method of administration, which has been approved by the 15 United States Food and Drug Administration (FDA) for the treatment of an opioid overdose. "Opioid antidote includes, but is 16 17 not limited to, naloxone hydrochloride, in any dosage amount, 18 which is administered through nasal spray or any other FDA-19 approved means or methods. c. The Commissioner of Human Services shall develop 20 21 informational materials concerning substance [abuse] use disorder treatment programs and resources and sterile syringe access 22 programs and resources, and information on the availability of 23 opioid antidotes, for dissemination to health care [professionals] 24 25 practitioners and first responders to facilitate the provision of 26 information to [patients pursuant to] persons who are treated for a 27 suspected overdose as provided in this section. 28 (cf: P.L.2017, c.285, s.1) 29 30 6. (New section) a. To the extent funds are made available by 31 the State for this purpose, a recognized place of public access shall 32 obtain a supply of opioid antidotes pursuant to a standing order 33 issued pursuant to section 4 of P.L.2013, c.46 (C.24:6J-4) or section 34 1 of P.L.2017, c.88 (C.45:14-67.2), which opioid antidotes shall be 35 maintained in one or more secure and easily accessible locations for 36 the purpose of administering the opioid antidote to any person who 37 is reasonably believed to be experiencing an opioid overdose. The 38 recognized place of public access shall acquire a supply of opioid 39 antidotes in quantities and types as shall be required by the 40 Commissioner of Human Services. Nothing in this section shall be 41 construed to limit, restrict, or otherwise prohibit any other person or 42 entity from obtaining, maintaining, distributing, or administering 43 opioid antidotes as authorized under section 4 of P.L.2013, c.46 44 (C.24:6J-4) or any other provision of law. 45 b. A recognized place of public access that acquires and 46 maintains a supply of opioid antidotes pursuant to subsection a. of 47 this section shall ensure that at least one employee or volunteer who 48 regularly provides services at, through, or on behalf of the

14

recognized place of public access has received training on the 1 2 standardized protocols for the administration of an opioid antidote 3 to a person who is reasonably believed to be experiencing an opioid 4 overdose, the requirements for which training shall be established 5 by the Commissioner of Human Services. The training and 6 protocols shall follow best practices for low-threshold community 7 use of opioid antidotes in recognized places of public access, and 8 shall include the overdose prevention information described in 9 subsection a. of section 5 of P.L.2013, c.46 (C.24:6J-5). The 10 commissioner may require by regulation that more than employee 11 or volunteer at a recognized place of public access complete the 12 training required pursuant to this subsection. 13 c. A recognized place of public access may, to the extent not

14 otherwise prohibited by State or federal law, enter into an 15 agreement with a community-based organization to distribute 16 opioid antidotes on the premises of the recognized place of public 17 access.

18

19 7. Section 2 of P.L.2018, c.106 (C.18A:40-12.24) is amended20 to read as follows:

2. a. Each board of education, board of trustees of a charter 22 school, and chief school administrator of a nonpublic school shall 23 develop a policy, in accordance with guidelines established by the 24 Department of Education pursuant to section 3 of this act, for the 25 emergency administration of an opioid antidote to a student, staff 26 member, or other person who is <u>reasonably believed to be</u> 27 experiencing an opioid overdose. The policy shall:

(1) require each school that includes any of the grades nine
through 12, and permit any other school, to obtain a standing order
for opioid antidotes pursuant to section 4 of the "Overdose
Prevention Act," P.L.2013, c.46 (C.24:6J-4), and to maintain a
supply of opioid antidotes under the standing order in a secure but
unlocked and easily accessible location; and

(2) [permit] <u>direct</u> the school nurse, or a trained employee
designated pursuant to subsection c. of this section, to administer an
opioid antidote to any person whom the nurse or trained employee
in good faith <u>reasonably</u> believes is experiencing an opioid
overdose.

b. (1) Opioid antidotes shall be maintained by a school pursuant
to paragraph (1) of subsection a. of this section in quantities and
types deemed adequate by the board of education, board of trustees
of a charter school, or chief school administrator of a nonpublic
school, in consultation with the Department of Education and the
Department of Human Services.

(2) The opioid antidotes shall be accessible in the school during
regular school hours and during school-sponsored functions that
take place in the school or on school grounds adjacent to the school
building. A board of education, board of trustees of a charter

school, or chief school administrator of a nonpublic school may, in
 its discretion, make opioid antidotes accessible during school sponsored functions that take place off school grounds.

4 c. (1) The school nurse shall have the primary responsibility 5 for the emergency administration of an opioid antidote in 6 accordance with a policy developed under this section. The board 7 of education, board of trustees of a charter school, or chief school 8 administrator of a nonpublic school shall designate additional 9 employees of the school district, charter school, or nonpublic school 10 who volunteer to administer an opioid antidote in the event that a 11 person [experiences] is reasonably believed to be experiencing an opioid overdose when the nurse is not physically present at the 12 13 The designated employees shall only be authorized to scene. 14 administer opioid antidotes after receiving the training required 15 under subsection b. of section 3 of this act] Nothing in this section 16 shall be construed to prohibit any other person from administering 17 an opioid antidote to a person who is reasonably believed to be experiencing an opioid antidote, if the administration is consistent 18 19 with the requirements of P.L.2013, c.46 (C.24:6J-1 et al.).

(2) In the event that a licensed athletic trainer volunteers to
administer an opioid antidote pursuant to this act, it shall not
constitute a violation of the "Athletic Training Licensure Act,"
P.L.1984, c.203 (C.45:9-37.35 et seq.).

d. A policy developed pursuant to this section shall require the
transportation of [an overdose victim] <u>a person reasonably believed</u>
to have experienced an overdose to a hospital emergency room by
emergency services personnel after the administration of an opioid
antidote, even if the person's symptoms appear to have resolved.
(cf: P.L.2018, c.106, s.2)

30

31 8. Section 3 of P.L.2018, c.106 (C.18A:40-12.25) is amended
32 to read as follows:

33 3. a. The Department of Education, in consultation with the 34 Department of Human Services and appropriate medical experts, shall establish guidelines for the development of a policy by a 35 school district, charter school, or nonpublic school for the 36 37 emergency administration of opioid antidotes. Each board of 38 education, board of trustees of a charter school, and chief school 39 administrator of a nonpublic school shall implement the guidelines 40 in developing a policy pursuant to section 2 of this act.

b. The guidelines shall include a requirement that each school
nurse, and each employee designated pursuant to subsection c. of
section 2 of this act, receive training on standardized protocols for
the administration of an opioid antidote to a person who
[experiences] is reasonably believed to be experiencing an opioid
overdose. The training shall include the overdose prevention
information described in subsection a. of section 5 of the "Overdose

ינ ה

16

Prevention Act," P.L.2013, c.46 (C.24:6J-5). The guidelines shall 1 2 specify an appropriate entity or entities to provide the training, and 3 a school nurse shall not be solely responsible to train the employees 4 designated pursuant to subsection c. of section 2 of this act. 5 (cf: P.L.2018, c.106, s.3) 6 7 9. Section 4 of P.L.2006, c.99 (C.26:5C-28) is amended to read 8 as follows: 9 4. a. In accordance with the provisions of section 3 of 10 P.L.2006, c.99 (C.26:5C-27), a municipality may establish or authorize establishment of a sterile syringe access program that is 11 12 approved by the commissioner to provide for the exchange of 13 hypodermic syringes and needles. 14 (1) A municipality that establishes a sterile syringe access 15 program, at a fixed location or through a mobile access component, 16 may operate the program directly or contract with one or more of 17 the following entities to operate the program: a hospital or other 18 health care facility licensed pursuant to P.L.1971, c.136 (C.26:2H-1 19 et seq.), a federally qualified health center, a public health agency, a 20 substance abuse treatment program, an AIDS service organization, 21 or another nonprofit entity designated by the municipality. These 22 entities shall also be authorized to contract directly with the 23 commissioner in any municipality in which the governing body has 24 authorized the operation of sterile syringe access programs by 25 ordinance pursuant to paragraph (2) of this subsection. The 26 municipality or entity under contract shall implement the sterile 27 syringe access program in consultation with a federally qualified health center and the New Jersey Office on Minority and 28 29 Multicultural Health in the Department of Health, and in a 30 culturally competent manner. 31 (2) Pursuant to paragraph (2) of subsection a. of section 3 of P.L.2006, c.99 (C.26:5C-27), a municipality whose governing body

32 33 has authorized the operation of sterile syringe access programs 34 within the municipality may require within the authorizing 35 ordinance that an entity as described in paragraph (1) of this 36 subsection obtain approval from the municipality, in a manner 37 prescribed by the authorizing ordinance, to operate a sterile syringe 38 access program prior to obtaining approval from the commissioner 39 to operate such a program, or may permit the entity to obtain 40 approval to operate such a program by application directly to the 41 commissioner without obtaining prior approval from the 42 municipality.

(3) Two or more municipalities may jointly establish or
authorize establishment of a sterile syringe access program that
operates within those municipalities pursuant to adoption of an
ordinance by each participating municipality pursuant to this
section.

1 b. A sterile syringe access program shall comply with the 2 following requirements:

3 (1) Sterile syringes and needles shall be provided at no cost to4 consumers 18 years of age and older;

5 (2) Program staff shall be trained and regularly supervised in: 6 harm reduction; substance use disorder, medical and social service 7 referrals; and infection control procedures, including universal 8 precautions and needle stick injury protocol; and programs shall 9 maintain records of staff and volunteer training and of hepatitis C 10 and tuberculosis screening provided to volunteers and staff;

(3) The program shall offer information about HIV, hepatitis C
and other bloodborne pathogens and prevention materials at no cost
to consumers, and shall seek to educate all consumers about safe
and proper disposal of needles and syringes;

15 (4) The program shall provide information and referrals to 16 consumers, including HIV testing options, access to medication-17 assisted substance use disorder treatment programs and other 18 substance use disorder treatment programs, and available health and 19 social service options relevant to the consumer's needs. The 20 program shall encourage consumers to receive an HIV test, and 21 shall, when appropriate, develop an individualized substance use 22 disorder treatment plan for each participating consumer;

(5) The program shall screen out consumers under 18 years of
age from access to syringes and needles, and shall refer them to
substance use disorder treatment and other appropriate programs for
youth;

(6) The program shall develop a plan for the handling and
disposal of used syringes and needles in accordance with
requirements set forth at N.J.A.C.7:26-3A.1 et seq. for regulated
medical waste disposal pursuant to the "Comprehensive Regulated
Medical Waste Management Act," P.L.1989, c.34 (C.13:1E-48.1 et
al.), and shall also develop and maintain protocols for postexposure treatment;

(7) (a) The program may obtain a standing order, pursuant to
the "Overdose Prevention Act," P.L.2013, c.46 (C.24:6J-1 et seq.),
authorizing program staff to carry and [dispense] distribute
naloxone hydrochloride or another opioid antidote to consumers
[and], to the family members and friends [thereof] of consumers,
and to any member of the general public;

(b) The program shall provide overdose prevention information
to consumers, the family members and friends [thereof] of
<u>consumers</u>, and [other persons associated therewith, as appropriate]
<u>members of the general public</u>, in accordance with the provisions of
section 5 of the "Overdose Prevention Act," P.L.2013, c.46
(C.24:6J-5);

46 (8) The program shall maintain the confidentiality of consumers
47 by the use of confidential identifiers, which shall consist of the first
48 two letters of the first name of the consumer's mother and the two-

digit day of birth and two-digit year of birth of the consumer, or by 1 2 the use of such other uniform Statewide mechanism as may be 3 approved by the commissioner for this purpose; 4 (9) The program shall provide a uniform identification card that 5 has been approved by the commissioner to consumers and to staff 6 and volunteers involved in transporting, exchanging or possessing 7 syringes and needles, or shall provide for such other uniform 8 Statewide means of identification as may be approved by the 9 commissioner for this purpose; 10 (10) The program shall provide consumers at the time of 11 enrollment with a schedule of program operation hours and 12 locations, in addition to information about prevention and harm 13 reduction and substance use disorder treatment services; and 14 (11) The program shall establish and implement accurate data 15 collection methods and procedures as required by the commissioner 16 for the purpose of evaluating the sterile syringe access programs, 17 including the monitoring and evaluation on a quarterly basis of: 18 (a) sterile syringe access program participation rates, including 19 the number of consumers who enter substance use disorder 20 treatment programs and the status of their treatment; (b) the effectiveness of the sterile syringe access programs in 21 22 meeting their objectives, including, but not limited to, return rates 23 of syringes and needles distributed to consumers and the impact of 24 the sterile syringe access programs on intravenous drug use; and 25 (c) the number and type of referrals provided by the sterile 26 syringe access programs and the specific actions taken by the sterile 27 syringe access programs on behalf of each consumer. 28 A municipality may terminate a sterile syringe access c. 29 program established or authorized pursuant to this act, which is 30 operating within that municipality, if its governing body approves 31 such an action by ordinance, in which case the municipality shall 32 notify the commissioner of its action in a manner prescribed by 33 regulation of the commissioner. 34 (cf: P.L.2017, c.131, s.104) 35 36 10. Section 1 of P.L.2017, c.88 (C.45:14-67.2) is amended to 37 read as follows: 38 1. a. Notwithstanding any other law or regulation to the 39 contrary, a pharmacist may dispense an opioid antidote to any 40 [patient] person or entity, regardless of whether the [patient] person or entity holds an individual prescription for the opioid 41 42 antidote, pursuant to a standing order issued by a prescriber or 43 pursuant to the standing order issued pursuant to subsection b. of 44 A pharmacist who dispenses an opioid antidote this section. 45 pursuant to this section shall comply with the provisions of the 46 "Overdose Prevention Act," P.L.2013, c.46 (C.24:6J-1 et al.). 47 b. The Commissioner of Health, or, if the commissioner is not 48 a duly licensed physician, the Deputy Commissioner for Public

19

Health Services, shall issue [, upon request by a pharmacist 1 2 licensed to practice in this State,] a standing order authorizing [the 3 pharmacist] all licensed pharmacists in the State to dispense an 4 opioid antidote to any [patient] individual or entity, regardless of 5 whether the [patient] individual or entity holds an individual 6 prescription for the opioid antidote [, provided the pharmacist 7 complies with the requirements of the "Overdose Prevention Act," 8 P.L.2013, c.46 (C.24:6J-1 et al.) . The Commissioner of Health 9 shall provide a copy of the standing order to the Board of 10 Pharmacy, which shall post a copy of the standing order on the 11 board's Internet website and transmit a copy of the standing order 12 to all licensed pharmacists in such a manner as the board deems 13 appropriate. 14 c. As used in this section: "Opioid antidote" means naloxone hydrochloride [,] or any other 15 [similarly acting] drug approved by the United States Food and 16 Drug Administration for [self-administration for] the treatment of 17 18 an opioid overdose. 19 ["Patient" means the same as that term is defined in section 3 of 20 P.L.2013, c.46 (C.24:6J-3). "Prescriber" means the same as that term is defined in section 3 21 22 of P.L.2013, c.46 (C.24:6J-3). 23 (cf: P.L.2017, c.88, s.1) 24 25 11. This act shall take effect 60 days after the date of enactment, but the Commissioner of Health, the Commissioner of Human 26 27 Services, and the Director of the Division of Consumer Affairs in 28 the Department of Law and Public Safety may each take any 29 anticipatory administrative action in advance as shall be necessary

30 for the implementation of this act.